Analysis population included all eligible participants whose data were retrieved from medical records and assessed.

Data for participants with following comorbidities were observed and reported: cerebrovascular disease,chronic pulmonary disease,congestive heart failure,connective tissue disease,dementia,diabetes with end organ damage,diabetes without end organ damage,depression,hemiplegia or paraplegia, history of myocardial infarction,human immunodeficiency virus/ acquired immunodeficiency syndrome,hypertension,mild liver disease (i.e., chronic hepatitis or cirrhosis without portal hypertension),moderate to severe liver disease (i.e., cirrhosis and portal hypertension),use of warfarin,moderate to severe renal disease (i.e., creatinine >3mg% [265 mcmol/l],dialysis,transplantation,uremic syndrome),ulcer disease,peripheral vascular disease,skin ulcers/cellulitis,horseshoe kidney,polycystic kidney disease,von hippel-lindau disease,chronic viral hepatitis, previous thyroid disorders. Categories with at least 1 non-zero data are reported below. One participant could have more than 1 comorbidities.

Analysis population included all eligible participants whose data were retrieved from medical records and assessed.

Participants with following insurance status were observed and reported: Private insurance only and public insurance.

Analysis population included all eligible participants whose data were retrieved from medical records and assessed.

Analysis population included all eligible participants whose data were retrieved from medical records and assessed. Here, 'overall number of participants analyzed' signifies number of participants evaluable for this outcome measure.

Analysis population included all eligible participants whose data were retrieved from medical records and assessed. Here, 'overall number of participants analyzed' signifies number of participants evaluable for this outcome measure.

Body mass index (BMI) is calculated as the body mass in kilograms divided by the square of the body height in meters.

Analysis population included all eligible participants whose data were retrieved from medical records and assessed. Here, 'overall number of participants analyzed' signifies number of participants evaluable for this outcome measure.

In this outcome measure participants diagnosed with mRCC between 2012 to 2018 were reported.

Analysis population included all eligible participants whose data were retrieved from medical records and assessed.

The American Joint Committee on Cancer (AJCC) stages were assigned. Stage I- defined as tumor of 7 cm across or smaller, while Stage II- defined as tumor larger than 7 cm across and did not spread to lymph nodes or distant organs, Stage III- defined as tumor was growing into a major vein (like the renal vein or the vena cava) or into tissue around the kidney, but it was not growing into the adrenal gland or beyond Gerota's fascia. There was no spread to lymph nodes or distant organs. Stage IV- defined as main tumor was growing beyond Gerota's fascia and may be growing into the adrenal gland on top of the kidney. It might or might not had spread to nearby lymph nodes. It had not spread to distant lymph nodes or other organs.

Analysis population included all eligible participants whose data were retrieved from medical records and assessed.

Participants with Memorial Sloan Kettering Cancer Center(MSKCC)model and International Metastatic Renal Cell Carcinoma Database Consortium(IMDC)criteria risks groups are reported.MSKCC model assessed as low(0),intermediate(1-2) or high risk(=>3)based on number of criteria present.Criteria=Karnofsky performance status(KPS)score <80,lactate dehydrogenase>1.5*upper limit of normal,hemoglobin<lower limit of normal, corrected serum calcium>10 mg/dL,time from first diagnosis of RCC to start of systemic therapy of<1 year.KPS score range:0=death to 100=no evidence of disease,higher score=higher ability to perform daily tasks.IMDC risk group stratifies participants in poor,intermediate(had 1 or 2 poor factors)and favorable(had no poor factors)risk groups based on number of adverse clinical,laboratory parameters.Poor factors included KPS score of<80 at initiation of treatment,time from diagnosis to metastasis treatment of<12 months,anemia,corrected calcium>10 mg/dL,neutrophilia,thrombocythemia.

Analysis population included all eligible participants whose data were retrieved from medical records and assessed. Here, "number analyzed" signifies the number of participants evaluable at specific category.

Number of participants with the sites of distant metastasis at initial metastatic diagnosis are reported in this outcome measure. Sites evaluated for distant metastasis were lymph nodes, bone, brain, liver, lung/pleura, adrenal gland, pancreas, others (peritoneum, surgical lodge, soft tissue, nephrectomy bed). One participant could have more than 1 sites of metastases.

Analysis population included all eligible participants whose data were retrieved from medical records and assessed.

The ECOG performance status was used to assess the effect of disease progression on participant's daily activities. ECOG performance status Grade 0: fully active, able to carry on all pre-disease performance without restriction; Grade 1: restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, Grade 2: ambulatory and capable of all self-care, but unable to carry out any work activities, up and about more than 50% of waking hours, Grade 3: capable of only limited self-care, confined to bed or chair for more than 50% of waking hours, Grade 4: completely disabled; cannot carry on any self-care; totally confined to bed or chair.

Analysis population included all eligible participants whose data were retrieved from medical records and assessed.

In this outcome measure participants with different treatment modalities including partial nephrectomy, radical nephrectomy, radiation therapy, neoadjuvant systemic therapy and adjuvant systemic therapy were reported. One participant could have more than 1 treatment modalities.

Analysis population included all eligible participants whose data were retrieved from medical records and assessed. Here, 'overall number of participants analyzed' signifies number of participants evaluable for this outcome measure.

In this outcome measure the duration form last treatment received including: partial nephrectomy, radical nephrectomy, radiation therapy, neoadjuvant systemic therapy and adjuvant systemic therapy was reported.

Analysis population included all eligible participants whose data were retrieved from medical records and assessed. Here, 'overall number of participants analyzed' signifies number of participants evaluable for this outcome measure.

Number of participants were classified and reported according to the number of treatment lines received including first-line, second-line and third-line or more after diagnosis of mRCC.

Analysis population included all eligible participants whose data were retrieved from medical records and assessed.

This outcome measure was analyzed by using Kaplan-Meier method.

Analysis population included all eligible participants whose data were retrieved from medical records and assessed. Here, "number analyzed" signifies the number of participants evaluable at specific category.

Analysis population included all eligible participants whose data were retrieved from medical records and assessed. Data for this outcome measure is reported for evaluable participants in all of three arms including 4/2 schedule, 4/2 to 2/1 schedule and 2/1 schedule.

Analysis population included all eligible participants whose data were retrieved from medical records and assessed. Here, 'overall number of participants analyzed' signifies number of participants evaluable for this outcome measure.Data for this outcome measure is reported for evaluable participants in arm 4/2 to 2/1 schedule only.

Number of participants with their reasons for switching to 2/1 schedule treatment including adverse event, local or professional protocol, participant decision, performance status and other (renal function deterioration; medical decision, site of cytoreductive surgery), were reported. One participant could have multiple reasons to switch to 2/1 treatment schedule.

Analysis population included all eligible participants whose data were retrieved from medical records and assessed. Data for this outcome measure is reported for evaluable participants in arm including 4/2 schedule only.

Analysis population included all eligible participants whose data were retrieved from medical records and assessed. Here, 'overall number of participants analyzed' signifies number of participants evaluable for this outcome measure. Data for this outcome measure is reported for evaluable participants in arms including 4/2 to 2/1 schedule only.

Participants who had a termination of sunitinib treatment for reasons other than regimen change or switch, disease progression, or death were reported as discontinued. Categories with at least 1 non-zero data are reported below. One participant could have more than 1 reason for discontinuation.

Analysis population included all eligible participants whose data were retrieved from medical records and assessed. Here, 'overall number of participants analyzed' signifies number of participants evaluable for this outcome measure.

Analysis population included all eligible participants whose data were retrieved from medical records and assessed. Data for this outcome measure is reported for evaluable participants in all of three arms including 4/2 schedule, 4/2 to 2/1 schedule and 2/1 schedule.

Participants who had change in the dose of sunitinib during the data identification period were reported. Categories with at least 1 non-zero data are reported below.

Analysis population included all eligible participants whose data were retrieved from medical records and assessed. Here, 'overall number of participants analyzed' signifies number of participants evaluable for this outcome measure. Data for this outcome measure is reported for evaluable participants in all of three arms including 4/2 schedule, 4/2 to 2/1 schedule and 2/1 schedule.

Best response includes complete response (CR): equal to disappearance of all target lesions; partial response (PR): greater than equal to (>=) 30% decrease in sum of longest dimensions of lesions taking as reference baseline sum longest dimensions; progressive disease (PD): >=20% increase in sum of longest dimensions of lesions taking as a reference smallest sum of the longest dimensions since treatment start, or the appearance of >=1 new lesion; stable disease (SD): neither shrinkage for PR or increase for PD taking as reference smallest sum of longest dimensions since treatment start; as well as response not assessed and unknown also reported.

Analysis population included all eligible participants whose data were retrieved from medical records and assessed.

Number of participants with different supportive care including anticoagulants, antibiotics, antidepressants, antidiarrheal, antiemetics, antifungals, antihistamines, antihypertensive medication, erythropoiesis stimulating agents (ESAs), granulocyte colony-stimulating factor (GSCF), hormone replacement, iron supplements, nutritional supplements, pain medications, platelet transfusion, red blood cell transfusion, steroids, topical skin care lotions/creams/moisturizers, other (pantoprazole) were reported. One participant could have more than 1 supportive care elements.

Analysis population included all eligible participants whose data were retrieved from medical records and assessed. Data for this outcome measure is reported for evaluable participants in arms including 4/2 schedule only.

An adverse event (AE) was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. AE was assessed according to severity; mild (not causing any significant problem, dose adjustment not required), moderate (caused problem that does not interfere significantly with usual activities or the clinical status, dose adjustment needed due to adverse event) and severe (caused problem that interferes significantly with usual activities or the clinical status, study drug stopped due to adverse event).

Analysis population included all eligible participants whose data were retrieved from medical records and assessed. Data for this outcome measure is reported for evaluable participants in all of three arms including 4/2 schedule, 4/2 to 2/1 schedule and 2/1 schedule.

Progression free survival (PFS) was based on Kaplan-Meier estimates. PFS was defined as time in months from start of treatment-to-treatment discontinuation due to disease progression as assessed by the investigator. PD: =>20% increase in sum of longest dimensions of lesions taking as a reference smallest sum of longest dimensions since treatment start or appearance of =>1 new lesions. Disease progression was determined from oncologic assessment data (where data meet the criteria for PD), or from death case report forms (CRFs). This outcome measure was analyzed by using Kaplan-Meier method.

Analysis population included all eligible participants whose data were retrieved from medical records and assessed.

PFS was based on Kaplan-Meier estimates. PFS was defined as time in months from start of treatment-to-treatment discontinuation due to disease progression as assessed by the investigator. PD: =>20% increase in sum of longest dimensions of lesions taking as a reference smallest sum of longest dimensions since treatment start or appearance of =>1 new lesions. Disease progression was determined from oncologic assessment data (where data meet the criteria for PD), or from death CRFs. This outcome measure was analyzed by using Kaplan-Meier method.

Analysis population included all eligible participants whose data were retrieved from medical records and assessed. Data for this outcome measure is reported for evaluable participants in arm including 4/2 schedule only.

PFS was based on Kaplan-Meier estimates. PFS was defined as time in months from start of treatment-to-treatment discontinuation due to disease progression as assessed by the investigator. PD: =>20% increase in sum of longest dimensions of lesions taking as a reference smallest sum of longest dimensions since treatment start or appearance of =>1 new lesions. Disease progression was determined from oncologic assessment data (where data meet the criteria for PD), or from death CRFs. This outcome measure was analyzed by using Kaplan-Meier method.

Analysis population included all eligible participants whose data were retrieved from medical records and assessed.

Overall survival (OS) was defined as the time from the start of treatment to the date of death due to any cause. If a participant was not known to have died, survival was censored at the date of last known date participant alive. Kaplan-Meier method was used for OS analysis. This outcome measure was analyzed by using Kaplan-Meier method.

Analysis population included all eligible participants whose data were retrieved from medical records and assessed.

OS was defined as the time from the start of treatment to the date of death due to any cause. If a participant was not known to have died, survival was censored at the date of last known date participant alive. Kaplan-Meier method was used for OS analysis. This outcome measure was analyzed by using Kaplan-Meier method.

Analysis population included all eligible participants whose data were retrieved from medical records and assessed. Data for this outcome measure is reported for evaluable participants in arm including 4/2 to 2/1 schedule only.

OS was defined as the time from the start of treatment to the date of death due to any cause. If a participant was not known to have died, survival was censored at the date of last known date participant alive. Kaplan-Meier method was used for OS analysis. This outcome measure was analyzed by using Kaplan-Meier method.

Analysis population included all eligible participants whose data were retrieved from medical records and assessed.

Analysis population included all eligible participants whose data were retrieved from medical records and assessed. Here, 'overall number of participants analyzed' signifies number of participants evaluable for this outcome measure.